IMR Press / FBL / Volume 18 / Issue 4 / DOI: 10.2741/4187

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

The canonical Wnt-beta-catenin pathway in development and chemotherapy of osteosarcoma

Show Less
1 Jinling Hospital, Dept Orthopedics, Nanjing Univ, Sch Med ,Nanjing 210002, Peoples R China
Academic Editor:Wei Qin
Front. Biosci. (Landmark Ed) 2013, 18(4), 1384–1391; https://doi.org/10.2741/4187
Published: 1 June 2013
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)
Abstract

The canonical Wnt-beta -catenin signaling pathway is a key component of normal skeletal development and disease. Alterations within this signaling pathway have been described in human and canine osteosarcoma (OS); however, debate exists as to whether or not alterations in this pathway contribute to OS development in humans. In metastatic OS, the Wnt-βcatenin pathway promotes the invasion and migration of OS cells and β-catenin acts as a biological marker of OS with the potential to metastasize to the lung. The participation of the Wnt-β-catenin pathway in OS development and metastasis is regulated by several factors, including hormones and alkaline phosphatase (ALP). This pathway is also involved in the resistance of OS to chemotherapy, especially in resistance to all three drugs used in standard chemotherapy, i.e. doxorubicin, cisplatin and methotrexate (MTX). In this review, we will summarize recent findings regarding the Wnt-β-catenin pathway in OS development and chemotherapy.

Keywords
Wnt-beta-catenin; Osteosarcoma; Development; Chemotherapy
Review
Share
Back to top